Atsena Therapeutics’ gene therapy takes aim at childhood blindness


May 23, 2022 -- Ophthalmology-based gene therapy company Atsena Therapeutics is focused on developing novel treatments for inherited forms of blindness, with an ongoing Phase I/II clinical trial evaluating a potential therapy for patients with Leber congenital amaurosis (LCA) 1.

"Gene therapy, broadly, we're learning a lot. The field is still relatively young. Within the eye itself, we're working on the approach to solve the delivery issue and getting the vector to the right cell types," Atsena Therapeutics CEO Patrick Ritschel told ScienceBoard.net at the American Society of Gene & Cell Therapy (ASGCT) 2022 annual meeting in Washington, DC.

Ritschel pointed to Atsena's laterally-spreading vector that can be administered "in one location in the eye and it will spread and cover the entire retina" to help solve the delivery issue.

LCA is the most common cause of blindness in children, impacting two to three per 100,000. LCA1 is caused by mutations in the guanylate cyclase 2D (GUCY2D) gene and results in early and severe vision impairment or blindness. LCA1-GUCY2D is one of the most common forms of LCA, affecting roughly 20% of patients who live with this inherited retinal disease.

Watch the video below to learn more.


How to address challenges in producing AAV vectors
There are challenges in producing sufficient quantities of gene therapy products, particularly when it comes to adeno-associated virus (AAV) vectors,...
Omega Therapeutics looks to tap 'nature's operating system' to control gene expression
Precision genomic medicine company Omega Therapeutics is looking to harness “nature’s operating system” for controlling gene expression and cell differentiation,...
Delivery of gene therapies remains a key challenge
Gene therapy holds great promise for treating inherited disorders, cancers, and other diseases, but delivery of these therapies remains a key challenge,...
Next evolution of CAR T-cell therapy is solid tumors
While chimeric antigen receptor (CAR) T-cell therapy has become a game changer for some patients with blood cancer, the next area of evolution for the...

Copyright © 2022 scienceboard.net

Last Updated 5/23/2022 1:42:21 PM